{"commentary":{"count":10,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":4,"x_thread":4,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06567743\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT06567743","nct_id":"NCT06567743","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06567743. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via the current instillation method","label":"Experimental: Cohort A, Arm 1","type":"EXPERIMENTAL"},{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.","label":"Experimental: Cohort A, Arm 2","type":"EXPERIMENTAL"},{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.","label":"Experimental: Cohort A, Arm 3","type":"EXPERIMENTAL"},{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.","label":"Experimental: Cohort B, Arm 1","type":"EXPERIMENTAL"},{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.","label":"Experimental: Cohort B, Arm 2","type":"EXPERIMENTAL"},{"description":"At all treatment visits cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method followed by gemcitabine instilled intravesically","label":"Experimental: Cohort CX, Arm 1","type":"EXPERIMENTAL"},{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method for two consecutive weeks, followed by gemcitabine administered intravesically in the third week on a cyclic 2:1 visit schedule basis","label":"Experimental: Cohort CX, Arm 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-30","type":"ESTIMATED"},"conditions":["High-Risk Non-Muscle-Invasive Bladder Cancer"],"enrollment":{"count":325,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cretostimogene Grenadenorepvec","type":"DRUG"}],"last_update":"2026-09-03","lead_sponsor":"CG Oncology, Inc.","official_title":"A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-03-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Cohort A (Arm 1 and 2): Complete response rate","timeFrame":"At 11 and 24 weeks"},{"measure":"Cohort A (Arm 3): High- Grade Event-Free Survival","timeFrame":"48 months"},{"measure":"Cohort B (Arm 1): Complete response rate","timeFrame":"At 11 and 24 weeks"},{"measure":"Cohort B (Arm 2): High-Grade Event-Free Survival","timeFrame":"48 months"},{"measure":"Cohort CX (Arms 1 and 2): High-Grade Event-Free Survival","timeFrame":"48 months"},{"measure":"Cohort CX (Arms 1 and 2): Safety","timeFrame":"48 months"}],"references":[],"start_date":{"date":"2024-09-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","url":"https://clinicaltrials.gov/study/NCT06567743"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06567743"}